CCCC - C4 Therapeutics Inc
NYSE * Health Care * Biotechnology
$2.90
+$0.01 (+0.35%)
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Key Statistics
Market Cap
$282.00M
P/B Ratio
1.10
EPS
$-1.27
Revenue Growth
+1.1%
Profit Margin
-2.9%
Employees
104
How CCCC Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#1
of 6
Size Rank
#6
of 6
C4 Therapeutics Inc Company Information
- Headquarters
- Massachusetts; U.S.A
- Website
- www.c4therapeutics.com
- Sector
- Health Care
- Industry
- Biotechnology